Revenue Update on Penumbra Inc(NYSE:PEN)

Penumbra Inc(NYSE:PEN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $65.11M. Analysts estimated a revenue of $58.18M. Earnings per share were $0.01. Analysts had estimated an EPS of $-0.07.

Penumbra Inc. is an interventional therapies company that designs develops manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and clinical needs across two markets which includes neuro and peripheral vascular. Its neuro products include Neurovascular Access Neuron Access System BENCHMARK Intracranial Access System Penumbra System 3D Penumbra Coil 400 Penumbra SMART Coil and LIBERTY stent. The Company’s neuro surgical tools include Apollo System. Its peripheral vascular products include Ruby Coil System Penumbra Occlusion Device (POD) and Indigo System. Its products address conditions which include ischemic stroke and hemorrhagic stroke which involve blockage or rupture of blood vessels in the brain and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures which involve the use of medical devices to remove or treat blockages or ruptures of blood vessels.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Penumbra Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Penumbra Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.